Deep immune profiling uncovers novel associations with clinical phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)

Christopher Redmond,Moses M Kitakule,Aran Son,McKella Sylvester,Keith Sacco,Ottavia Delmonte,Francesco Licciardi,Riccardo Castagnoli,Cecilia Poli,Yasmin Espinoza,Camila Astudillo,Sarah E Weber,Gina A Montealegre Sanchez,Karyl Barron,Mary Magliocco,Kerry Dobbs,Yu Zhang,Helen Matthews,Cihan Oguz,Helen C Su,Luigi D Notarangelo,Pamela A Frischmeyer-Guerrerio,Daniella M Schwartz

DOI: https://doi.org/10.1101/2022.08.31.22279265

2022-09-02

MedRxiv

Abstract:Multisystem Inflammatory Syndrome in Children (MIS-C) is a systemic inflammatory condition that follows SARS-CoV2 infection or exposure in children. Clinical presentations are highly variable and include fever, gastrointestinal (GI) disease, shock, and Kawasaki Disease-like illness (MIS-C/KD). Compared to patients with acute COVID, patients with MIS-C have a distinct immune signature and expansion of TRVB11 expressing T cells. However, the relationship between immunological and clinical phenotypes of MIS-C is unknown. Here, we measured serum biomarkers, TCR repertoire, and SARS-CoV2-specific T cell responses in a cohort of 76 MIS-C patients. Serum biomarkers associated with macrophage and Th1 activation were elevated in patients with shock, consistent with previous reports. Significantly increased SARS-CoV-2-induced IFN-γ, IL-2, and TNF-α production were seen in CD4 + T cells from patients with neurologic involvement and respiratory failure. Diarrhea was associated with a significant reduction in shock-associated serum biomarkers, suggesting a protective effect. TRVB11 usage was highly associated with MIS-C/KD and coronary aneurysms, suggesting a potential biomarker for these manifestations in MIS-C patients. By identifying novel immunologic associations with the different clinical phenotypes of MIS-C, this study provides insights into the clinical heterogeneity of MIS-C. These unique immunophenotypic associations could provide biomarkers to identify patients at risk for severe complications of MIS-C, including shock and MIS-C/KD.